ArticleJournal of magnetic resonance imaging : JMRI2025
Multi-Scale Spatial Heterogeneity of Liver Fibrosis Evaluated by MR Elastography in Rat Models.
Article in Journal of magnetic resonance imaging : JMRI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Segmental fECV measurement using PCD-CT as an early predictor of liver function decline in chronic liver disease.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWhile liver stiffness heterogeneity by MR elastography (MRE) is clinically important, whether MRE reflects multi-scale liver fibrosis heterogeneity and explains histopathological-MRE staging discordance remains unclear. PURPOSE: To assess spatial heterogeneity of liver fibrosis at multiple scales using MRE, correlating with histopathology. STUDY TYPE: Prospective. ANIMAL MODEL: Male Sprague-Dawley rats (N = 72) with liver fibrosis via carbon tetrachloride intoxication or bile duct ligation (N = 27 in each) and sham controls (N = 18). FIELD STRENGTH/SEQUENCE: 3.0 T spin-echo echo-planar imaging multi-frequency (60-200 Hz) three-dimensional vector MRE sequence. ASSESSMENT: Three-dimensional vector MRE at 200 Hz quantified liver stiffness across four lobes. Liver fibrosis heterogeneity was evaluated at three scales via histopathology and MRE: whole-liver (≥ 2 stage difference; liver stiffness variability as percentage difference between highest and lowest mean lobar stiffness), inter-lobe (1-3 stage difference; stiffness comparisons between paired lobes), and intra-lobe (≥ 2 stage difference between predominant and secondary fibrosis patterns; coefficient of variation of stiffness). STATISTICAL TESTS: Spearman correlation, Kruskal-Wallis test with Dunn correction, area under the receiver operating characteristic curves (AUC), and DeLong's test. p < 0.05 was considered significant.
resultsFibrotic livers (2.84 ± 0.59 kPa) showed significantly higher stiffness than non-fibrotic livers (1.90 ± 0.23 kPa). AUCs for fibrosis staging were lower at the rat level (0.78-0.94) than at the lobe level (0.94-0.98), significant for ≥ F2 and ≥ F3 stages. Based on optimal cutoffs, liver stiffness variability classified 80.6% (58/72) of whole-liver heterogeneity, and CV of liver stiffness identified 85.5% (53/62) of intra-lobe heterogeneity. Additionally, liver stiffness detected 75% (120/160) of inter-lobe heterogeneity. MRE-defined heterogeneity explained 70.6% (whole-liver scale) and 78.6% (intra-lobe scale) of cases with ≥ 2 stage MRE-histopathology discordance. DATA
conclusionMRE depicts multi-scale hepatic fibrosis heterogeneity that correlates with histopathology and may provide a mechanism to explain histopathological-MRE staging discordance, potentially improving diagnostic accuracy with sampling limitations. EVIDENCE LEVEL: 1. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.